Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/29388
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | |
dc.contributor.author | GOMES, Fernando L. T. | |
dc.contributor.author | MARANHAO, Raul C. | |
dc.contributor.author | TAVARES, Elaine R. | |
dc.contributor.author | CARVALHO, Priscila O. | |
dc.contributor.author | HIGUCHI, Maria L. | |
dc.contributor.author | MATTOS, Fernando R. | |
dc.contributor.author | PITTA, Fabio G. | |
dc.contributor.author | HATAB, Sergio A. | |
dc.contributor.author | KALIL-FILHO, Roberto | |
dc.contributor.author | SERRANO JR., Carlos V. | |
dc.date.accessioned | 2018-11-21T17:00:33Z | |
dc.date.available | 2018-11-21T17:00:33Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, v.23, n.6, p.561-569, 2018 | |
dc.identifier.issn | 1074-2484 | |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/29388 | |
dc.description.abstract | In previous studies, it was demonstrated that lipid core nanoparticles (LDE) resemble the low-density lipoprotein structure and carrying the antiproliferative agent paclitaxel (PTX) strongly reduced atherosclerosis lesions induced in rabbits by cholesterol feeding. Currently, the aim was to verify whether combining LDE-PTX treatment with methotrexate (MTX) associated with LDE (LDE-MTX) could accelerate the atherosclerosis regression attained with single LDE-PTX treatment, after withdrawing the cholesterol feeding. Thirty-eight rabbits were fed 1% cholesterol chow for 8 weeks. Six of these rabbits were then euthanized for analyses of the aorta (controls). In the remaining rabbits, cholesterol feeding was withdrawn, and those 32 animals were allocated to 3 groups submitted to different 8-week intravenous treatments, all once/week: LDE-PTX (n = 10; 4 mg/kg), LDE-PTX + LDE-MTX (n = 11; 4 mg/kg), and LDE-alone (n = 11). Rabbits were then euthanized and aortas were excised for morphometric, immunohistochemical, and gene expression analyses. After cholesterol feeding withdrawal, in comparison with LDE-alone group, both LDE-PTX and LDE-PTX + LDE-MTX treatments had the ability to increase the regression of plaque areas: -49% in LDE-PTX and -59% for LDE-PTX + LDE-MTX. However, only LDE-PTX + LDE-MTX treatment elicited reduction in the intima area, estimated in -57%. Macrophage presence in aortic lesions was reduced 48% by LDE-PTX and 43% by LDE-PTX + LDE-MTX treatment. Matrix metalloproteinase 9 was reduced by either LDE-PTX (74%) or LDE-PTX + LDE-MTX (78%). Tumor necrosis factor gene expression was reduced 65% by LDE-PTX and 79% by LDE-PTX + LDE-MTX. In conclusion, treatment with LDE-PTX indeed accelerated plaque reduction after cholesterol feeding; LDE-PTX + LDE-MTX further increased this effect, without any observed toxicity. These results pave the way for the use of combined chemotherapy to achieve stronger effects on aggravated, highly inflamed atherosclerotic lesions. | |
dc.language.iso | eng | |
dc.publisher | SAGE PUBLICATIONS INC | |
dc.relation.ispartof | Journal of Cardiovascular Pharmacology and Therapeutics | |
dc.rights | restrictedAccess | |
dc.subject | atherosclerosis treatment | |
dc.subject | drug-targeting | |
dc.subject | methotrexate | |
dc.subject | paclitaxel | |
dc.subject | solid lipid particles | |
dc.subject.other | rich microemulsion lde | |
dc.subject.other | low-density-lipoprotein | |
dc.subject.other | plasma kinetics | |
dc.subject.other | tumor uptake | |
dc.subject.other | in-vitro | |
dc.subject.other | disease | |
dc.subject.other | nanoemulsion | |
dc.subject.other | macrophages | |
dc.subject.other | carmustine | |
dc.subject.other | pharmacokinetics | |
dc.title | Regression of Atherosclerotic Plaques of Cholesterol-Fed Rabbits by Combined Chemotherapy With Paclitaxel and Methotrexate Carried in Lipid Core Nanoparticles | |
dc.type | article | |
dc.rights.holder | Copyright SAGE PUBLICATIONS INC | |
dc.identifier.doi | 10.1177/1074248418778836 | |
dc.identifier.pmid | 29779420 | |
dc.subject.wos | Cardiac & Cardiovascular Systems | |
dc.subject.wos | Pharmacology & Pharmacy | |
dc.type.category | original article | |
dc.type.version | publishedVersion | |
hcfmusp.author.external | HATAB, Sergio A.:Univ Fed Espirito Santo, Hosp Cassiano Antonio de Moraes, Vitoria, ES, Brazil | |
hcfmusp.description.beginpage | 561 | |
hcfmusp.description.endpage | 569 | |
hcfmusp.description.issue | 6 | |
hcfmusp.description.volume | 23 | |
hcfmusp.origem | WOS | |
hcfmusp.origem.id | WOS:000447563400010 | |
hcfmusp.origem.id | 2-s2.0-85047377709 | |
hcfmusp.publisher.city | THOUSAND OAKS | |
hcfmusp.publisher.country | USA | |
hcfmusp.relation.reference | Aikawa M, 1998, CIRCULATION, V97, P2433, DOI 10.1161/01.CIR.97.24.2433 | |
hcfmusp.relation.reference | Azevedo CHM, 2005, GYNECOL ONCOL, V97, P178, DOI 10.1016/j.ygyno.2004.12.015 | |
hcfmusp.relation.reference | Feio DCA, 2017, INT J NANOMED, V12, P3827, DOI 10.2147/IJN.S129153 | |
hcfmusp.relation.reference | Barquera S, 2015, ARCH MED RES, V46, P328, DOI 10.1016/j.arcmed.2015.06.006 | |
hcfmusp.relation.reference | Bentzon JF, 2014, CIRC RES, V114, P1852, DOI 10.1161/CIRCRESAHA.114.302721 | |
hcfmusp.relation.reference | BONNEY RJ, 1975, CANCER RES, V35, P1950 | |
hcfmusp.relation.reference | Bulgarelli A, 2013, CARDIOVASC DRUG THER, V27, P531, DOI 10.1007/s10557-013-6488-3 | |
hcfmusp.relation.reference | Chan ESL, 2010, NAT REV RHEUMATOL, V6, P175, DOI 10.1038/nrrheum.2010.5 | |
hcfmusp.relation.reference | Daminelli EN, 2016, CARDIOVASC DRUG THER, V30, P433, DOI 10.1007/s10557-016-6675-0 | |
hcfmusp.relation.reference | Dias MLN, 2007, CANCER CHEMOTH PHARM, V59, P105, DOI 10.1007/s00280-006-0252-3 | |
hcfmusp.relation.reference | Francis AA, 2011, EXP CLIN CARDIOL, V16, P77 | |
hcfmusp.relation.reference | FRIEDMAN M, 1963, AM J PATHOL, V43, P349 | |
hcfmusp.relation.reference | Gu C, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00266 | |
hcfmusp.relation.reference | Hall TC, 1996, EUR J CANCER, V2, P135 | |
hcfmusp.relation.reference | Hungria VTM, 2004, CANCER CHEMOTH PHARM, V53, P51, DOI 10.1007/s00280-003-0692-y | |
hcfmusp.relation.reference | Khanna V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077037 | |
hcfmusp.relation.reference | Libby P, 1996, CURR OPIN LIPIDOL, V7, P330, DOI 10.1097/00041433-199610000-00012 | |
hcfmusp.relation.reference | Libby P, 2012, ARTERIOSCL THROM VAS, V32, P2045, DOI 10.1161/ATVBAHA.108.179705 | |
hcfmusp.relation.reference | Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262 | |
hcfmusp.relation.reference | Lo Prete AC, 2006, J PHARM PHARMACOL, V58, P801, DOI 10.1211/jpp.58.6.0010 | |
hcfmusp.relation.reference | Maranhao RC, 2008, ATHEROSCLEROSIS, V197, P959, DOI 10.1016/j.atherosclerosis.2007.12.051 | |
hcfmusp.relation.reference | Maranhao RC, 2017, EXPERT OPIN DRUG DEL, V14, P1217, DOI 10.1080/17425247.2017.1276560 | |
hcfmusp.relation.reference | Maranhao RC, 2015, EXPERT OPIN DRUG DEL, V12, P1135, DOI 10.1517/17425247.2015.999663 | |
hcfmusp.relation.reference | Maranhao RC, 2015, CURR PHARM DESIGN, V21, P1196, DOI 10.2174/1381612820666141013150714 | |
hcfmusp.relation.reference | MARANHAO RC, 1994, CANCER RES, V54, P4660 | |
hcfmusp.relation.reference | MARANHAO RC, 1993, LIPIDS, V28, P691, DOI 10.1007/BF02535988 | |
hcfmusp.relation.reference | Maranhao RC, 2002, CANCER CHEMOTH PHARM, V49, P487, DOI 10.1007/s00280-002-0437-3 | |
hcfmusp.relation.reference | MARANHAO RC, 1992, BRAZ J MED BIOL RES, V25, P1003 | |
hcfmusp.relation.reference | Moore KJ, 2013, NAT REV IMMUNOL, V13, P709, DOI 10.1038/nri3520 | |
hcfmusp.relation.reference | Moura JA, 2011, INT J NANOMED, V6, P2285, DOI 10.2147/IJN.S18039 | |
hcfmusp.relation.reference | Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2 | |
hcfmusp.relation.reference | Newby AC, 2008, ARTERIOSCL THROM VAS, V28, P2108, DOI 10.1161/ATVBAHA.108.173898 | |
hcfmusp.relation.reference | Parameswaran N, 2010, CRIT REV EUKAR GENE, V20, P87, DOI 10.1615/CritRevEukarGeneExpr.v20.i2.10 | |
hcfmusp.relation.reference | Pinheiro KV, 2006, CANCER CHEMOTH PHARM, V57, P624, DOI 10.1007/s00280-005-0090-8 | |
hcfmusp.relation.reference | Pires L, 2009, CANCER CHEMOTH PHARM, V63, P281, DOI 10.1007/s00280-008-0738-2 | |
hcfmusp.relation.reference | Rodrigues DG, 2005, CANCER CHEMOTH PHARM, V55, P565, DOI 10.1007/s00280-004-0930-y | |
hcfmusp.relation.reference | ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247 | |
hcfmusp.relation.reference | ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507 | |
hcfmusp.relation.reference | Shiozaki AA, 2016, CLINICS, V71, P435, DOI 10.6061/clinics/2016(08)05 | |
hcfmusp.relation.reference | SMALL DM, 1984, J CLIN INVEST, V73, P1590, DOI 10.1172/JCI111366 | |
hcfmusp.relation.reference | Tavares ER, 2011, INT J NANOMED, V6, P2297, DOI 10.2147/IJN.S24048 | |
hcfmusp.relation.reference | Teixeira RS, 2004, J PHARM PHARMACOL, V56, P909, DOI 10.1211/0022357023826 | |
hcfmusp.relation.reference | Wang SS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136026 | |
hcfmusp.relation.reference | Zelova H, 2013, INFLAMM RES, V62, P641, DOI 10.1007/s00011-013-0633-0 | |
dc.description.index | MEDLINE | |
dc.identifier.eissn | 1940-4034 | |
hcfmusp.citation.scopus | 30 | |
hcfmusp.scopus.lastupdate | 2024-04-12 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MCP Artigos e Materiais de Revistas Científicas - HC/InCor Artigos e Materiais de Revistas Científicas - LIM/11 Artigos e Materiais de Revistas Científicas - LIM/31 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_GOMES_Regression_of_Atherosclerotic_Plaques_of_CholesterolFed_Rabbits_by_2018.PDF Restricted Access | publishedVersion (English) | 1.77 MB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.